[go: up one dir, main page]

BR9811744A - Conjugados contendo o homeodomìnio de antenapédia - Google Patents

Conjugados contendo o homeodomìnio de antenapédia

Info

Publication number
BR9811744A
BR9811744A BR9811744-0A BR9811744A BR9811744A BR 9811744 A BR9811744 A BR 9811744A BR 9811744 A BR9811744 A BR 9811744A BR 9811744 A BR9811744 A BR 9811744A
Authority
BR
Brazil
Prior art keywords
antenapedia
homeodomain
conjugates containing
region
conjugates
Prior art date
Application number
BR9811744-0A
Other languages
English (en)
Inventor
Andrea Crisanti
Original Assignee
Imp College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp College Innovations Ltd filed Critical Imp College Innovations Ltd
Publication of BR9811744A publication Critical patent/BR9811744A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Variable-Direction Aerials And Aerial Arrays (AREA)

Abstract

Patente de Invenção: "CONJUGADOS QUE CONTêM O HOMEODOMìNIO DE ANTENAPéDIA". Um conjugando compreendendo: (a) uma primeira região, compreendendo o homeodomínio de antenapédia ou de uma variante da mesma; e (b) uma segunda região não naturalmente associada com a primeira região, compreendendo uma proteína de pelo menos 60 aminoácidos.
BR9811744-0A 1997-09-02 1998-09-02 Conjugados contendo o homeodomìnio de antenapédia BR9811744A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9718609.2A GB9718609D0 (en) 1997-09-02 1997-09-02 Fusion protein
PCT/GB1998/002628 WO1999011809A1 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia

Publications (1)

Publication Number Publication Date
BR9811744A true BR9811744A (pt) 2002-01-02

Family

ID=10818419

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811744-0A BR9811744A (pt) 1997-09-02 1998-09-02 Conjugados contendo o homeodomìnio de antenapédia

Country Status (10)

Country Link
US (2) US7968512B2 (pt)
EP (1) EP1009847A1 (pt)
JP (1) JP2001514858A (pt)
AU (1) AU737829B2 (pt)
BR (1) BR9811744A (pt)
CA (1) CA2301157A1 (pt)
GB (1) GB9718609D0 (pt)
IL (2) IL134602A0 (pt)
NZ (1) NZ503007A (pt)
WO (1) WO1999011809A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505055A (ja) * 1996-12-02 2001-04-17 ウエイク・フオレスト・ユニバーシテイ Ｈｉｖ感染の治療としてのｈｉｖコレセプターの不活性化
AU1818299A (en) * 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
GB2346616B (en) 1998-11-13 2004-04-21 Cyclacel Ltd Transport vectors
JP2004513059A (ja) * 1998-12-24 2004-04-30 ユセベ，ソシエテ　アノニム ペプチド産物、方法及び組成物
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
EP1118668A1 (en) * 2000-01-07 2001-07-25 ARTEMIS Pharmaceuticals GmbH Transduction of recombinases for inducible gene targeting
IL150510A0 (en) * 2000-01-07 2003-02-12 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
GB0003284D0 (en) * 2000-02-15 2000-04-05 Secr Defence Brit Anti-viral therapy
IL151909A0 (en) * 2000-04-12 2003-04-10 Implyx Ltd Peptide conjugates for drug delivery
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
KR100374050B1 (ko) * 2000-07-26 2003-03-03 최수영 세포침투성 융합단백질, 이를 코딩하는 재조합폴리뉴클레오타이드 및 발현벡터
US20030027335A1 (en) * 2000-09-07 2003-02-06 Ruley H. Earl Genome engineering by cell-permeable DNA site-specific recombinases
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
CA2452865A1 (en) * 2001-06-07 2002-12-12 Skinmedica, Inc. Conditioned cell culture media and uses thereof
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
GB0124391D0 (en) * 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
DE102007041655A1 (de) 2007-09-03 2009-03-05 Medicyte Gmbh Vermehrung von primären Zellen und deren Verwendung
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
WO2010119249A1 (en) 2009-04-14 2010-10-21 Trojan Technologies Ltd. Therapeutic antennapedia-antibody molecules and methods of use thereof
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
US20140296154A1 (en) * 2011-05-06 2014-10-02 Yale University Method of preventing development of psoriatic lesions
ES2633343T3 (es) 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal
CA2870155C (en) 2012-04-09 2024-04-30 Case Western Reserve University Compositions and methods for inhibiting the activity of lar family phosphatases
EP2861238A4 (en) 2012-06-05 2016-03-16 Capricor Inc OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
JP6433896B2 (ja) 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸
US10301629B2 (en) * 2013-06-11 2019-05-28 Portage Pharmaceuticals Ltd. Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
EP2927685A1 (en) 2014-04-02 2015-10-07 Medicyte GmbH Suitable hepatocytes for in-vitro hepatitis tests
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
DK3265110T3 (da) 2015-03-02 2020-10-19 The Board Of Trustees Of The Univ Of Illionis Peptider til inhibering af angiogenese
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11124553B2 (en) 2016-04-07 2021-09-21 Case Western Reserve University TDP-43 mitochondrial localization inhibitor for the treatment of neurogenerative disease
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CA3064463A1 (en) 2017-07-11 2019-01-17 Case Western Reserve University Compositions and methods for treating myelin disorders
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives

Also Published As

Publication number Publication date
EP1009847A1 (en) 2000-06-21
US8735340B2 (en) 2014-05-27
GB9718609D0 (en) 1997-11-05
US7968512B2 (en) 2011-06-28
JP2001514858A (ja) 2001-09-18
AU737829B2 (en) 2001-08-30
IL134602A0 (en) 2001-04-30
NZ503007A (en) 2000-11-24
US20080317773A1 (en) 2008-12-25
IL134602A (en) 2006-10-31
CA2301157A1 (en) 1999-03-11
US20110256168A1 (en) 2011-10-20
AU8877698A (en) 1999-03-22
WO1999011809A1 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
BR9811744A (pt) Conjugados contendo o homeodomìnio de antenapédia
BR9915548A (pt) Proteìnas de fusão de interferon-beta e usos
CY1108007T1 (el) Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
LU91342I2 (fr) Byetta-exénatide
EP0611573A3 (en) Bioactive cellulose amino compounds conjugates.
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
EE9800306A (et) Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad
BRPI9810519B1 (pt) derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
BR9808348A (pt) Alimento medicinal para diabéticos
BR9709395A (pt) Calçado aperfeiçoado
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
BR9807655A (pt) Uso de inibidores de lipase gastrintestinal.
BR9808875A (pt) Combinação de analgésicos
GB9606040D0 (en) Active peptide
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
PT1012186E (pt) Utilizacao de produto(s) da proteina kgf e de produto(s) da proteina glp-2 para a preparacao de um medicamento
BR9811643A (pt) Suplementação quìmica de osso
BR9714376A (pt) Antagonistas de somatostatina
BR9910454A (pt) Preparações efervescentes
BR9713514A (pt) Novo uso de creatina
ES2179375T3 (es) Composiciones farmaceuticas estabilizadas, a base de quinupristina y de dalfopristina y su preparacion.
ES2151970T3 (es) Peptidos dotados de actividad anti-inflamatoria.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO - DE ACORDO COM O ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B15K Others concerning applications: alteration of classification

Ipc: C12N 15/87 (2006.01), A61K 47/62 (2017.0